Regeneron

Actualités

Reuters - Il y a 4 jours

Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug

BUZZ-Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug ** Shares of drugmaker Amgen AMGN.O fall 1% to $324.95 ** Truist Securities downgrades stock to "hold" from "buy", citing "extremely competitive" landscape for an experimental drug to treat atopic dermatitis or eczema ** Brokerage also raises PT to $33

Reuters - Il y a 1 semaine

Teva to pay $450 million to resolve US kickback, price-fixing cases

UPDATE 1-Teva to pay $450 million to resolve US kickback, price-fixing cases Adds details on settlement, background of case throughout By Nate Raymond BOSTON, Oct 10 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspired to fix prices for generic drugs.

Reuters - Il y a 1 semaine

Clearside jumps as eye disease drug succeeds in mid-stage trial

BUZZ-Clearside jumps as eye disease drug succeeds in mid-stage trial ** Shares of drug developer Clearside Biomedical CLSD.O rise ~38.5% to $2.05 premarket ** Company says its drug CLS-AX showed stable vision in patients with wet age-related macular degeneration for up to 6 months compared to Regeneron Pharmaceuticals' REGN.O aflibercept, during a

Reuters - Il y a 2 semaines

Regeneron Pharmaceuticals Says Acquired IPR&D Charge Expected To Negatively Impact Q3 Adjusted EPS By About $0.43

BRIEF-Regeneron Pharmaceuticals Says Acquired IPR&D Charge Expected To Negatively Impact Q3 Adjusted EPS By About $0.43 Oct 7 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PHARMACEUTICALS - EXPECTS Q3 RESULTS WILL INCLUDE ACQUIRED IPR&D CHARGE OF ABOUT $56 MILLION ON PRE-TAX BASIS REGENERON PHARMACEUTICALS INC - ACQUIRED IPR&D CHARGE

Reuters - Il y a 2 semaines

Regeneron loses key defense in 19 treatment patent lawsuit

Regeneron loses key defense in COVID-19 treatment patent lawsuit By Blake Brittain Oct 4 - Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented invent

Reuters - Il y a 2 semaines

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +3.9% Diamondback Energy Inc FANG.OQ +3.7% NVIDIA Corp NVDA.OQ +3.0% Paccar Inc PCAR.OQ +2.8% Trade Desk Inc TTD.OQ +2.2% Bottom Performers Percent Change Tesla Inc TSLA.OQ -3.9% Warner Bros Discovery Inc WBD.OQ -3.5% Take-Two Interactive Software Inc TTWO.OQ -2.9% Moderna Inc MRNA.OQ -2.8% Regeneron Pharmaceuticals Inc REGN.OQ -2.8% The Nasdaq 100

Reuters - Il y a 3 semaines

U.S. stocks weekly: Streaking in September

RPT-BUZZ-U.S. stocks weekly: Streaking in September Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fl

Reuters - Il y a 3 semaines

U.S. stocks weekly: Streaking in September

BUZZ-U.S. stocks weekly: Streaking in September ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fleet of foot: Materials sprint to front of the pack, while Energ

Reuters - Il y a 3 semaines

U.S. STOCKS IonQ, Cassava Sciences, MeridianLink

BUZZ-U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.

Reuters - Il y a 3 semaines

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.

Reuters - Il y a 3 semaines

Regeneron rises as US FDA approves Dupixent for 'smoker's lung'

BUZZ-Regeneron rises as US FDA approves Dupixent for 'smoker's lung' ** Shares of Regeneron Pharmaceuticals REGN.O rise 1.6% to $1,056.92 in early trading ** Co and French partner Sanofi SASY.PA say the U.S. FDA has approved their blockbuster drug, Dupixent, for patients with a chronic lung disease commonly known as "smoker's lung" ** Dupixent is t

Reuters - Il y a 3 semaines

Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'

UPDATE 2-Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung' Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8 By Sriparna Roy Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.

Reuters - Il y a 3 semaines

Dupixent approved in United States as first-ever biologic medicine for patients with COPD

BRIEF-Dupixent approved in United States as first-ever biologic medicine for patients with COPD Sept 27 (Reuters) - Sanofi SA SASY.PA /REGENERON REGN.O : PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WITH COPD PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WI

Reuters - Il y a 3 semaines

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung' Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday. Reporting by Sriparna Roy in Bengaluru; Editi

Reuters - Il y a 3 semaines

What to Watch in the Day Ahead - Friday, September 27

What to Watch in the Day Ahead - Friday, September 27 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Federal Reserve Board Governor Michelle Bowman is set to participate in a conversation before the Alabama Bankers Association Bank CEO Meeting in Birmingham, Alabama.

Reuters - Il y a 3 semaines

Amgen falls after reporting mixed data on two drugs

BUZZ-Amgen falls after reporting mixed data on two drugs ** Shares of Amgen AMGN.O fall as much as 4.4% to a near two-month low of $316.22 ** Stock is set for its worst day in nearly two months if losses hold ** Late on Tuesday drugmaker said its drugs Uplizna and rocatinlimab, for a rare muscular disorder and a skin disease, respectively, met the

Reuters - Il y a 3 semaines

Amgen's muscular disorder drug meets main goal in late-stage study

UPDATE 4-Amgen's muscular disorder drug meets main goal in late-stage study Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Adds analyst comments in paragraphs 4, 10 and 11, trial data in paragraph 3, 8 and 9, exec comment in paragraph 6 By Bhanvi Satija and Puyaan Singh Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday that its drug helped improve daily activities includ

Reuters - Il y a 3 semaines

Regeneron falls after Leerink Partners downgrades to 'market perform', cuts PT

BUZZ-Regeneron falls after Leerink Partners downgrades to 'market perform', cuts PT Updates * * Shares of drugmaker Regeneron REGN.O fall 4.09% to $1,047.29 ** Brokerage Leerink Partners downgrades co to "market perform" from "outperform," cuts PT to $1,077 from $1,175 ** Says trigger for the downgrade was a court ruling for co's 2 milligram dose version of eye-care drug Eylea ** On Monday, a federal judge in West Virginia said REGN cannot immediately block U.S.

Reuters - Il y a 3 semaines

Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

UPDATE 1-Amgen gets early win in Regeneron lawsuit over Eylea biosimilar Adds reponse from Regeneron to Sept 23 story in paragraph 4, corrects company locations in paragraphs 8 and 9 By Blake Brittain Sept 23 (Reuters) - Regeneron REGN.O cannot immediately block U.S. sales of rival Amgen's AMGN.O proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.

Reuters - Il y a 3 semaines

Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Regeneron

Actualités

Conditions

Actifs populaires

Chat en direct XM